

The Future of Mesenchymal Stromal Cells in cancer – A Bibliometric Analysis

Dómhnall J O'Connor (✉ domhnalloconnor@gmail.com)

National University of Ireland Galway <https://orcid.org/0000-0003-1208-9869>

Laura R Barkley

NUIG: National University of Ireland Galway

Michael J Kerin

NUI Galway: National University of Ireland Galway

Primary research

Keywords: Mesenchymal Stromal Cell, Bibliometric Analysis, Translational Research, Mesenchymal Stem Cell, Cancer, Neoplasia

Posted Date: November 5th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-101314/v1>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background

Mesenchymal stromal/stem cells have garnered much interest in the field of cancer biology. Bibliometric analysis of a scientific field has the potential to reveal insights pertaining to the maturity of the field, the hotspot sources of publication and temporal shifts in research subcategories within the field. Despite the benefits of such an analysis, one has not been conducted to date.

Methods

The Web of Science™ database and VOSviewer software were used to analyse publication and citation data for all publications relating to Mesenchymal Stromal/Stem Cells in oncology. Contributions to the literature were also identified by country, journal and cancer type. Keyword analysis identified trends in developing research categories.

Results

9927 published articles were analysed. The current publication rate fits an exponential trend ($r^2 = 0.97$). The U.S. and the People's Republic of China have the highest overall publications but when corrected for population and citations per article, the most successful countries are Singapore, Luxembourg and Switzerland. In the past 15 years 74% of articles have been in cancer specific journals. Breast cancer publications account for 42% of common cancer articles. Most articles were published in journals that had a basic science focus (44%). Keyword analysis resulted in 3 distinct clusters aligned with 1. Characterisation and nomenclature, 2. Clinical and 3. Molecular function. The most recent publications favour topics on Molecular function.

Conclusions

Research on Mesenchymal Stromal/Stem Cells in oncology is experiencing exponential growth. There is widespread acceptance of basic science research on MSCs in cancer specific journals and a niche for more translational and clinically focused studies.

Background

In the 1980's Friedenstein and Owen described a fibroblastic cell that was isolated from the bone marrow of rodents and formed colonies when cultured *in vitro*. The described population were a heterogeneous collection of cells whose differentiation could be manipulated *in vitro* and were labelled "bone marrow osteogenic stem cells" (1, 2). In 1991 the term "Mesenchymal Stem Cell" was coined to describe these multipotent progenitors, a term which has persisted (3). Subsequently the International Society for Cellular Therapy (ISCT) recommended an amendment to the nomenclature. In a 2006 position paper the term 'Mesenchymal Stromal Cell' (MSC) was recommended for the description of these cells. The ISCT paper was in response to inter-investigator variability in cell isolation, expansion and characterisation and

aimed to standardise scientific reporting and acknowledge the variability in cells determined by their tissue of origin (4).

Aside from their multipotent differentiation, other functions of MSCs have been uncovered that demonstrate potential for translational application particularly in tissue healing and autoimmune conditions (5–7). MSCs have also garnered much interest in the field of cancer research. Authors have demonstrated that MSCs home to the site of tumours and can have a pro-tumorigenic influence (8). MSCs native to the cancer's tissue of origin have also been implicated (9, 10).

Within the tumour microenvironment (TME) the pro-tumorigenic influences of MSCs include induction of angiogenesis (11) promotion of cancer cell migration (10) and epithelial to mesenchymal transition (EMT) (12) the latter of which constitutes enhanced resistance to chemotherapies (12, 13). More recently, the immunosuppressive abilities of MSCs have been particularly interesting as they allow for the cancer to evade the immune response of the host (14, 15).

Prior to the digital age any given field of study would command a small number of print publications from which new findings could be accessed. The coming of the digital age has provided researchers with access to a quantity of data that was heretofore unimaginable. There is now a growing expanse of print and electronic sources. The freedom and speed with which knowledge is disseminated confers an obvious benefit but also presents a challenge. Experimentation is based on a hypothesis, which in turn is generated from robust knowledge of the prior research. In an era of monumental research output, incomplete knowledge of prior research can lead to error in study design (16).

Bibliometric analysis, conceived by Paul Otlet in 1934, provides a solution for a robust understanding of the ocean of print and digital data. Bibliometrics focuses on the data related to the reading and writing of books and documents rather than the content which would be the focus of a traditional literature review (17). By utilising the advancements in bibliometric and indexing software, one can access large volumes of publication metadata and draw conclusions about the trends of a particular field of study, the untapped niches and the maturity of that scientific field. Employing bibliometrics, researchers have been able to analyse whole research fields to provide insights in HIV (18), cancer (19) and microRNAs (20) among others.

Despite the benefits of bibliometric analyses and the growth of the field of MSCs in oncology, analysis of the topic has not been conducted to date. To conduct such an analysis would highlight areas of the globe producing high quality research, sites of highest productivity, evidence of trends and topics requiring further exploration.

Methods

Bibliometric data and search strategy

The *Web of Science*[™] (WoS) database, produced by Clarivate Analytics was accessed. The *WoS core collection* comprising of the following was interrogated; *Science Citation Index Expanded* (SCI-Expanded), *Social Sciences Citation Index* (SSCI), *Arts & Humanities Citation Index* (A&HCI), *Emerging Sources Citation Index* (ESCI), *Conference Proceedings Citation Index - Science* (CPCI-S), *Conference Proceedings Citation Index - Social Sciences & Humanities* (CPCI-SSH), *Book Citation Index– Science* (BKCI-S), *Book Citation Index– Social Sciences & Humanities* (BKCI-SSH), *Current Chemical Reactions* (CCR-Expanded) and *Index Chemicus* (IC) (21).

The search terms used were “Mesenchymal Stromal Cells” and “Mesenchymal Stem Cells” with the Boolean operator “OR”. Initial results were further refined using the WoS category “Oncology”. Duplicates were identified and removed. All languages and years of publication were included, as were all publication types. Data extracted included; Title, Author names, abstract, place of publication, language, year of publication, publishing journal, type of publication, WoS Category, number of citations and H-Index.

All data were extracted on a single day in April 2019 as WoS is an open database which is regularly updated with new publications. The use of a single source bibliometric database was conducted due to its comprehensive indexing of journals, suitability and extensive use for similar analyses in the literature (20, 22–24).

The description of publishing journals, on their journal website was accessed. The focus of journals as either cancer specific or general scientific was determined. Journals were deemed to have a cancer specific focus if their description included any of the following terms; cancer, tumour, tumor, malignancy, oncology, neoplasia, carcinoma or carcinogenesis and generalised science if they had none of the above terms in their description. Journals were also categorised based on their focus on either basic, translational or clinical research by the same process. Descriptors indicating a basic science focus included the following; basic science, basic biology, bench research, preclinical, laboratory, cell biology or molecular. Descriptors of a translational focus; translation, bench-to-bedside, translational and a clinical focus if; clinical, surgical, clinical trial or clinic were included. Journals that had more than one research focus were recorded in each of the relevant categories. The top 6 most common cancers and top 5 most common causes of cancer death as per the World Health Organisation (25) were recorded among search results.

Data analysis and visualisation

All data were input into *Microsoft Excel 2010* © for the generation of graphical data. WoS data tools were used for the generation of several elements of data analysis eg. generating citation reports, H-Indices and WoS categorisation.

The Java program VOSviewer (version 1.6.11) (26) was used to provide a keyword cluster analysis. To perform this a network visualisation was conducted using search result titles, authors, institutions and

abstracts input in .txt format. Co-occurrence of key words was performed for all key words that appear in the search results a minimum of 10 times.

Results

In total, our search strategy yielded 9,927 publications across the field of Mesenchymal Stem/Stromal Cells in cancer research, spanning a period of 32 years. From the first publication in 1986 there was a gradual increase in the number of publications. From the year 2000 onwards, the field gained significant momentum and grew annually to a maximum of 1410 publications in 2017. The growth rate of publications fits an exponential trend with an R^2 value of 0.97 (Fig. 1A) There were 341,359 citations of papers published in this field during this period and an average number of citations of 34.39 per publication (Fig. 1B). The average citations per article peaked in 1998 and trended downwards thereafter (Fig. 1C). The H-Index for the field was 223. The H-Index is used as a measure of the success of a field, in this instance 223 of the publications achieved 223 citations or more (27). The H-index and total number of citations peaked circa 2006–2008, plateaued and dropped as the number of total publications spiked a decade later (Fig. 1D). The spike in both H-index and average number of citations per article (Fig. 1C) precede the significant exponential growth from the year 2000 onwards (Fig. 1A). The trend of total publications and those relating to citations have a somewhat inverse relationship to one another. This relationship is intuitive when considered; in the beginning there were only a small number of publications from which future authors could cite, as the number of publications increased so did the citations of those fewer, older papers. After a point however there was a significant repository of papers, each of which received less citations and prominence.

Publications by country

90 countries in total contributed to the field of MSCs and oncology during this time. The top 25 countries are illustrated in Fig 2A. Of the 90 countries publishing on this topic, 59.5% of the publications come from the United States and the Peoples' Republic of China. To further outline the contribution of each country, the citation data from each country was analysed as were their number of publications in respect of population size. Among the top 25 countries by average citation, the contribution has a more balanced distribution (Fig 2B.), and is led by Singapore 61, Luxembourg 60 and Switzerland 55. These same 3 countries publish the most per 100,000 of the population as per the United Nations Population Division (28) as illustrated in Fig 2C. When corrected for population size several countries move up the ranks e.g. Finland, Ireland and Denmark while others no longer appear in the top 25 e.g. Japan, the Peoples' Republic of China or Spain (Fig 2A and 2C).

Research Focus

Figure 3A shows the top 15 journals in this field during this period. The top publishing journal in this field was Stem Cells (1156) followed by Oncotarget (837) and Cancer Research (571). Focusing exclusively on the past 15 years the publishing journals were explored in more detail. In 2004, 38% of the papers

investigating MSCs in oncology were published in journals with a cancer specific focus. From 2004 to 2018 there was a steady increase in publications in cancer specific journals which was highest in 2018 at 84% of all publications. In total over the 15-year period 74% of all publications occurred in these cancer specific journals (Fig. 3B). This demonstrates that there is good acceptance of papers on MSCs in oncology among the mainstream cancer research community and that its growth has been considerable between 2004–2018.

To further consider the nature of studies conducted in this area of research, publications were classified as basic, translational or clinical research based on the journal they were published in. Figure 3C demonstrates quite clearly that basic science publications are the most prevalent followed by clinical and translational. This trend was consistent over the 15 years represented in the graph. In 2004 basic science accounted for 39% of publications and experienced a marginal gain to 46% in 2018. The publication of clinical science papers remained relatively steady accounting for 33% in 2004 and again in 2018. While basic science had a marginal gain over the 15 years, there was a consequent loss in the prevalence of translational research publications which went from 27% in 2004 to 21% 15 years later.

To provide insight into the most commonly researched malignancies in the field, the 9927 publications were filtered for specific cancers. This process was limited to the most common cancers (Fig. 4A) and the most common causes of cancer mortality (Fig. 4B), according to the World Health Organisation publications (25). The most common cancer to be published on in this field was breast cancer (42% of publications), followed by lung (17%) and colorectal (14%) (Fig. 4C). Of these most common cancers, breast accounts for 22% of cases worldwide, lung 22% and colorectal 19% (Fig. 4A). The distribution of mortality is lung 37%, colorectal 18% and breast 13% (Fig. 4B). These results demonstrate that breast cancer is disproportionately represented in the published literature, in respect of its prevalence worldwide and contribution to cancer related mortality.

Keyword analysis

Title, authors, abstracts and keywords were extracted for all of the 9927 publications as detailed above and a specific focus on keyword occurrence was undertaken.

The relevant output is provided by VOSviewer in the form of a bubble plot. Each keyword that achieved the threshold for occurrences can be identified as a single bubble. The frequency with which any particular keyword appears corresponds to the size of the respective bubble. Proximity between bubbles is inversely related to the frequency with which they co-occur in the published literature. In line with this, VOSviewer grouped keywords into 3 separate general clusters relating to; characterisation and nomenclature (Fig. 5A red), clinical focus (Fig. 5A blue) and molecular function in cancer biology (Fig. 5A green). The most prevalent keywords were “Mesenchymal Stem Cell”, “Metastasis”, “emt” (Epithelial to Mesenchymal Transition) and “Bone Marrow”.

The VOSviewer output for keyword analysis was also stratified according to the temporal frequency of keywords within the literature. In Fig. 5B older terms are coloured blue and the most recent terms are coloured yellow. In considering this particular figure there is a temporal shift from keywords relating to isolation and characterisation of MSCs eg. “donor”, “mesenchymal stem cell”, “bone marrow”, to their involvement in TME eg. “e-cadherin”, “emt”, “microRNA” (Fig. 5B). This finding is consistent with the original efforts by researchers to isolate, identify and culture these cells *in vitro* until a standardisation of this process was established. After such a point that there was general consensus about the nomenclature and characterisation of these cells, new avenues pertaining to their function within the context of cancer biology was possible. It is worth noting that the cluster pertaining to clinical focus (Fig. 5A blue), has the fewest keywords and some of the least frequently identified in the literature. This finding provides an insight into the current state of MSCs in clinical cancer research. The 3 most prominent keywords within the clinical focus cluster are “review”, “case” and “concept”, leading us to believe that clinical research in this field is currently in its infancy with much of the published literature being of a theoretical nature, rather than applied clinical research.

Discussion

By utilising the techniques of bibliometric analysis, it is possible to access a large repository of publications and make certain judgements regarding the field of interest based on bibliometric parameters. The unique strength of bibliometric analysis over a traditional literature review is that the analysis facilitates the input of a far greater number of articles, which in turn constitutes more meaningful recommendations to researchers. From the outset of this paper, the aim of the authors was to make a commentary on the current state of the field of MSCs in cancer research and provide insights into which research streams are worthy of attention in the future.

Our analysis has included almost 10,000 publications from which the field of MSCs in oncology has been assessed and the publication data shows considerable growth within the field over the past 20 years, peaking in 2017. Less publications in 2018 however, does not preclude the possibility that the field is still undergoing continued growth. It has been noted previously that delayed indexing of published articles on the WoS platform can result in an underrepresentation of the publication statistics for more recent years (20). Another reason for the drop in 2018 can be attributed to the natural progression of the field commonly seen in bibliometric analyses. As research fields become more mature and publications of a rudimentary nature saturate the field, research naturally shifts towards more novel niches of investigation. Turning points such as this have been documented in numerous fields of study previously (29, 30). When considering the publications from 2018, one must also make a note of nomenclature. Mesenchymal Stromal Cells are closely related to the alternatively named Cancer Associated Fibroblasts (CAFs), both of which are fibroblastic cells that support cancer proliferation, survival, chemoresistance and immune-evasion in the TME (31). An increase in the use of the “CAF” terminology may also have contributed to the number of MSC publications in 2018.

Development of research fields is said to follow four stages; initially only a small number of contributors publish on a topic until the field receives wider acceptance and enjoys exponential growth. Upon saturation of the field, publications plateau at maturity until an ultimate decline in publications (32, 33). Based on the data we have presented and the strong R^2 value of 0.97, the field of MSCs in cancer research are currently undergoing the exponential phase of growth similar to that seen in other fields of study (33). This identified trend in the field of MSCs in cancer research is encouraging news for prospective cell biologists and cancer researchers with an interest in the TME, as it indicates a continued appetite for this type of research among the scientific community.

The citation data also aligns itself with the aforementioned 4 phases of research field maturity. In the early phases, the small number of publications were highly cited as interest in the field grew, resulting in more publications. The consequence of this high output however corresponded with an exponential decrease in the number of citations per item, the inverse of publication volume. While this citation bias is understandable as the field matures, researchers need to have an awareness of such phenomena when considering the merit of prior research and should also seek out the high citation articles that provided the foundation for the field's subsequent exponential growth.

Geographically, this field receives contribution from many jurisdictions, with over 90 countries contributing. The United States and the Peoples' Republic of China account for a significant volume. Both of these countries have been identified previously as power houses for publishing research in the field of cancer and others (34–38). Despite their high overall output, correction for population has highlighted research hotspots such as Luxembourg, Switzerland and Singapore who lead the world in publications per capita but also have the highest average citations among all countries. In considering collaborative working, these findings can inform researchers within this field of study. Particularly, when collaborations are sought within Europe, the impressive performances of Luxembourg and Switzerland make institutions from those countries worthy of research partnerships.

In relation to the journals that publish most prolifically, there is a mix of dedicated cell biology journals such as "Stem Cells" but also those with a broader cancer research focus such as "Oncotarget". Over time, publications on MSCs in oncology were increasingly seen in journals with a deliberate cancer focus (Fig. 3B), this suggests that while publications were originally in journals dedicated to studying cells eg. "Stem Cells", future research will be most appropriately published in cancer journals. This finding is a positive development as it demonstrates a wider acceptance of MSC research in the cancer community rather than exclusively the interest of cell biologists.

As a field matures, it is expected that publications will shift from preclinical to translational and ultimately clinical. This process has been studied in detail by Weber et al. who describe the challenge of accurately determining what stage a field is at by bibliometric analysis (39). In our attempt to make this determination about MSCs in cancer research we have taken a similar approach to Narin et al, whereby publishing journals were designated as either basic, translational or clinical and their publication data was subsequently analysed over time (40) (Fig. 3C). Our findings demonstrate strong predominance of

basic science/preclinical research which increased over a 15 year period. One may expect that basic science research would decrease overtime while translational and clinical publications increased. At this point that is not the case and there seems to be a continued appetite for bench research on MSCs in cancer. In the interest of developing future projects this indicates that while, basic science studies are still in demand, the aspiring cancer researcher who incorporates translational or clinical components will fill a relatively unmet need within the literature.

Of the cancers analysed, studies on breast cancer were most frequently published. The proportion of publications relating to breast cancer exceeded both its incidence and rate of mortality relative to the other cancers examined. This finding is not particularly novel as other bibliometric analyses indicate that breast cancer predominates various cancer research fields (41, 42) and also enjoys considerable funding (43). For those embarking on research involving MSCs in oncology, the implications of this finding are twofold. Firstly, institutions publishing on breast cancer have an established process and a strong track record of published outputs, making them promising collaborators. Secondly, given the near saturation of publications relating to breast cancer, the lesser studied cancers may contain novel findings that remain uncovered.

The keyword analysis (Fig. 5A&B) provides an insight into the content of published articles relating to MSCs in cancer research. There are a number of familiar keywords among the more prevalent in the literature, for example "Mesenchymal Stem Cell" and "emt". Epithelial to Mesenchymal Transition (emt) has long been identified as a mechanism by which MSCs support tumour progression and cancer cell survival within the TME (44). Furthermore, EMT has previously been identified as a research hotspot in cancer research, by bibliometric analysis (45). While its frequency within the literature supports its importance in MSC research and the expertise that exists within the scientific community, the search for novelty is likely to be found elsewhere within the cluster analysis. The cluster relating to clinical research (Fig. 5A blue), is noticeably underdeveloped compared to the other two. Prominent keywords such as "case", "concept" and "review" suggest that original, applied MSC research in this area is underrepresented. Consistent with the underdevelopment of translational research, this cluster demonstrates a need for future research on MSCs in oncology that has a translational or clinical component. The cluster analysis also demonstrates the change in keyword prevalence over time within the literature (Fig. 5B). The older terms along this spectrum include "Mesenchymal Stem Cell", "Media", "Osteoblast" and "Bone Marrow" and are almost exclusively situated within the cluster relating to the identification and characterisation of these cells. This is not peculiar as earlier research will be expected to focus on identification of MSCs in tumours and determining their characteristics. Conversely, the more current keywords include the aforementioned "emt" along with "microRNA", "Metastasis" and "e cadherin" all of which reside within the cluster pertaining to molecular function (Fig. 5A green). The temporal shift towards MSC function in the TME alongside our other data certainly suggest that future directions in the field will be on the functional elements of MSCs and how these can be manipulated to clinical and therapeutic advantage.

Conclusion

Bibliometric analysis has allowed for the assessment of over 9000 publications relating to the field of MSCs in cancer research. It has demonstrated exponential growth in the outputs of the field over the past 2 decades that persists. Analysis of research focuses and publishing countries have highlighted global hotspots of activity but also research quality. The acceptance of this field of study in mainstream cancer research and lag in clinical based publications can aid investigators in this field in hypothesis generation for future studies. Heeding the temporal shift of important keywords in the published literature will enable researchers to design new studies of enhanced scientific merit that harness essential bench research and transition it into the clinical setting.

List Of Abbreviations

MSC – Mesenchymal Stromal Cell

ISCT – International Society for Cell therapy

TME – Tumour Microenvironment

EMT – Epithelial to Mesenchymal transition

WoS – Web of Science

Declarations

Ethics approval and consent to participate

– Not applicable

Consent for publication

– Not applicable

All data generated and/or analysed during this study are included in this published article

Competing interests

– The authors declare that they have no competing interests

Funding

– There was no funding for the conduct of this study

Author contributions

- All authors have made substantial contributions to the generation of this submitted work and have approved the submitted version

Acknowledgements

- Not applicable

References

1. Owen M. Marrow stromal stem cells. *J Cell Sci Suppl.* 1988;10:63-76.
2. Owen M, Friedenstein AJ. Stromal stem cells: marrow-derived osteogenic precursors. *Ciba Found Symp.* 1988;136:42-60.
3. Caplan AL. Mesenchymal stem cells. *J Orthop Res.* 1991 Sep;9(5):641-50.
4. Dominici M, Le Blanc K, Mueller I et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy.* 2006;8(4):315-7.
5. Liang J, Zhang H, Kong W et al. Safety analysis in patients with autoimmune disease receiving allogeneic mesenchymal stem cells infusion: a long-term retrospective study. *Stem Cell Res Ther.* 2018 11 14;;9(1):312.
6. Gerdoni E, Gallo B, Casazza S et al. Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. *Ann Neurol.* 2007 Mar;61(3):219-27.
7. Lee RH, Seo MJ, Reger RL et al. Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. *Proc Natl Acad Sci U S A.* 2006 Nov 14;;103(46):17438-43.
8. Kucerova L, Matuskova M, Hlubinova K, Altanerova V, Altaner C. Tumor cell behaviour modulation by mesenchymal stromal cells. *Mol Cancer.* 2010 May 28;;9:129.
9. Li W, Zhang X, Wu F et al. Gastric cancer-derived mesenchymal stromal cells trigger M2 macrophage polarization that promotes metastasis and EMT in gastric cancer. *Cell Death Dis.* 2019 Dec 04;;10(12):918.
10. Karnoub AE, Dash AB, Vo AP et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. *Nature.* 2007 Oct 04;;449(7162):557-63.
11. Li G, Zhang H, Zhao Q et al. Mesenchymal stem cells promote tumor angiogenesis via the action of transforming growth factor β 1. *Oncology Letters.* 2016 Feb;11(2):1089-94.
12. Jing Y, Han Z, Liu Y et al. Mesenchymal stem cells in inflammation microenvironment accelerates hepatocellular carcinoma metastasis by inducing epithelial-mesenchymal transition. *PLoS ONE.*

- 2012;7(8):e43272.
13. Xue Z, Wu X, Chen X et al. Mesenchymal stem cells promote epithelial to mesenchymal transition and metastasis in gastric cancer through paracrine cues and close physical contact. *J Cell Biochem.* 2015 Apr;116(4):618-27.
 14. Lakins MA, Ghorani E, Munir H, Martins CP, Shields JD. Cancer-associated fibroblasts induce antigen-specific deletion of CD8 + T Cells to protect tumour cells. *Nat Commun.* 2018 03 05;;9(1):948.
 15. Chakravarthy A, Khan L, Bensler NP, Bose P, De Carvalho DD. TGF- β -associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure. *Nat Commun.* 2018 11 08;;9(1):4692.
 16. Ioannidis JPA, Greenland S, Hlatky MA et al. Increasing value and reducing waste in research design, conduct, and analysis. *Lancet.* 2014 Jan 11;;383(9912):166-75.
 17. Rousseau R. Forgotten founder of bibliometrics. *Nature.* 2014 -06;510(7504):218-.
 18. Michon F, Tummers M. The dynamic interest in topics within the biomedical scientific community. *PLoS ONE.* 2009 Aug 07;;4(8):e6544.
 19. Glynn RW, Chin JZ, Kerin MJ, Sweeney KJ. Representation of cancer in the medical literature—a bibliometric analysis. *PLoS ONE.* 2010 Nov 09;;5(11):e13902.
 20. Casey M, Kerin MJ, Brown JA, Sweeney KJ. Evolution of a research field—a micro (RNA) example. *PeerJ.* 2015;3:e829.
 21. Web of Science Core Collection Help [Internet].; 2018. Available from: http://images.webofknowledge.com/WOKRS513R8.1/help/WOS/hp_database.html.
 22. Jin B, Wu X, Du S. Top 100 most frequently cited papers in liver cancer: a bibliometric analysis. *ANZ J Surg.* 2020 JAN;90(1-2):21-6.
 23. Li G, Lin J, Jiang C, Feng Q, Wen L. Trends in chronic hepatitis B treatment-related research from 1973 to 2018: a bibliometric and visual analysis. *J Int Med Res:UNSP* 0300060519893234.
 24. Zhong Q, Li B, Zhu Q, Zhang Z, Zou Z, Jin Y. The Top 100 Highly Cited Original Articles on Immunotherapy for Childhood Leukemia. *Front Pharmacol.* 2019 SEP 24;10:1100.
 25. Stewart BW, Wild CP, editors. *World Cancer Report 2014.* 1st ed. Lyon, France: International Agency for Research on Cancer; 2014.
 26. van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. *Scientometrics.* 2010 Aug;84(2):523-38.
 27. Bornmann L, Daniel H. The state of h index research Is the h index the ideal way to measure research performance? *EMBO Rep.* 2009 JAN;10(1):2-6.
 28. Countries in the world by population [Internet]. [cited April, 2019]. Available from: <https://www.worldometers.info/world-population/population-by-country/>.
 29. Hernández-Torrano D, Ibrayeva L. Thinking skills and creativity. *Thinking skills and creativity.* 2006;35:100625.

30. Liu F, Wu T, Lei G et al. Worldwide tendency and perspectives in traumatic dental injuries: a bibliometric analysis over two decades (1999-2018). *Dent Traumatol*. 2020 Mar 13,.
31. Borriello L, Nakata R, Sheard MA et al. Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells. *Cancer Res*. 2017 09 15;;77(18):5142-57.
32. Dabi Y, Darrigues L, Katsahian S et al. Publication Trends in Bariatric Surgery: a Bibliometric Study. *Obes Surg*. 2016 April 7;;26(11):2691-9.
33. Keathley-Herring H, Aken EV, Gonzalez-Aleu F, Deschamps F, Letens G, Orlandini PC. Assessing the maturity of a research area: bibliometric review and proposed framework. *Scientometrics*. 2016;109(2):927-51.
34. El-Alfy EM, Mohammed SA. A review of machine learning for big data analytics: bibliometric approach. *Technol Anal Strateg Manage*.
35. Wu M, Wang Y, Yan C, Zhao Y. Study on subclinical hypothyroidism in pregnancy: a bibliometric analysis via CiteSpace. *J Matern -Fetal Neonatal Med*.
36. Huang L, Chen K, Zhou M. Climate change and carbon sink: a bibliometric analysis. *Environ Sci Pollut Res*. 2020 MAR;27(8):8740-58.
37. Zhu Y, Li JJ, Reng J, Wang S, Zhang R, Wang B. Global trends of *Pseudomonas aeruginosa* biofilm research in the past two decades: A bibliometric study. *MicrobiologyOpen*:e1021.
38. Gao Y, Shi S, Ma W et al. Bibliometric analysis of global research on PD-1 and PD-L1 in the field of cancer. *Int Immunopharmacol*. 2019 JUL;72:374-84.
39. Weber GM. Identifying translational science within the triangle of biomedicine. *J Transl Med*. 2013 MAY 24;11:126.
40. Narin F, Pinski G, Gee HH. Structure of the Biomedical Literature. *Journal of the American Society for Information Science*. 1976;27(1):25-45.
41. Cabral BP, da Graça Derengowski Fonseca M, Mota FB. The recent landscape of cancer research worldwide: a bibliometric and network analysis. *Oncotarget*. 2018 Jul 17;;9(55):30474-84.
42. Glynn RW, Chin JZ, Kerin MJ, Sweeney KJ. Representation of cancer in the medical literature—a bibliometric analysis. *PLoS ONE*. 2010 Nov 09;;5(11):e13902.
43. Begum M, Lewison G, Lawler M, Sullivan R. Mapping the European cancer research landscape: An evidence base for national and Pan-European research and funding. *Eur J Cancer*. 2018 09;100:75-84.
44. Santamaria PG, Moreno-Bueno G, Portillo F, Cano A. EMT: Present and future in clinical oncology. *Mol Oncol*. 2017 JUL;11(7):718-38.
45. Zhai X, Zhao J, Wang Y et al. Bibliometric Analysis of Global Scientific Research on lncRNA: A Swiftly Expanding Trend. *Biomed Res Int*. 2018;2018:7625078.

Figures




Figure 1

Overall Publications and Citations. (A) Total number of publications by year and exponential line of best fit (B) Total number of citations by year (C) Citations per article by year and (D) H – index for the entire field by year.




Figure 2

Global variations in publication and citation. (A) Top 25 countries according to overall publication volume(B) Top 25 countries according to the average number of citations per article(C) Top 25 countries according to the volume of publications per 100,000 of population.






Figure 3

Publishing Journals. (A) Most prolific journals publishing in this field (B) Articles published in a journal with a cancer specific focus over the past 15 years (C) Articles published in journals with a basic science (Blue), Translational Science (Red) or a Clinical Science (Green) focus.




Figure 4

Cancers of Interest. (A) 6 most common cancers worldwide according to the WHO (29) (B) 5 most common causes of cancer death worldwide (29) (C) The proportional representation of the above cancers in the literature.




Figure 5

Keyword Analysis. (A) Bubble plot of keywords organised in 3 distinct clusters; Characterisation and nomenclature (Red), Clinical focus (Blue) and Molecular function (Green) (B) Bubble plot of keywords coloured according to their appearance in the literature, as indicated by the inset legend, keywords at the blue end of the spectrum were the oldest and those on the yellow end are more recent.